Article
Hematology
Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, Jose Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico
Summary: AITL is a subtype of PTCL with distinct features and poor prognosis. A new prognostic score (AITL score) combining age, ECOG performance status, CRP, and beta 2 microglobulin was developed. Disease progression within 24 months (POD24) was a powerful prognostic factor.
Article
Multidisciplinary Sciences
Mario Bunse, Janina Pfeilschifter, Julia Bluhm, Maria Zschummel, Jara J. Joedicke, Anthea Wirges, Helen Stark, Vivien Kretschmer, Markus Chmielewski, Wolfgang Uckert, Hinrich Abken, Joerg Westermann, Armin Rehm, Uta E. Hoepken
Summary: The study demonstrates that CAR-T cells targeting CXCR5 effectively inhibit tumor growth by depleting both B cells and follicular T helper cells in lymphoma models, suggesting a promising treatment strategy for nodal B-NHLs.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Ziyuan Shen, Shuo Zhang, Meng Zhang, Lingling Hu, Qian Sun, Chenlu He, Dongmei Yan, Jingjing Ye, Hao Zhang, Ling Wang, Weiying Gu, Yuqing Miao, Qinhua Liu, Changli Ouyang, Junfeng Zhu, Chunling Wang, Taigang Zhu, Shuiping Huang, Wei Sang
Summary: This study found that the ferritin-based nomogram enhances the prognostic value of DLBCL, providing better predictions for the outcome of the disease.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Yong-Pyo Lee, Sang Eun Yoon, Junhun Cho, Young Hyeh Ko, Hyunji Jo, Seok Jin Kim, Won Seog Kim
Summary: This study compared the suitability of five scoring systems in Tfh cell lymphoma and found that the AITL score performed the best in classification, while the IPI and international T-cell lymphoma project index showed better performance in predicting survival rates. However, there are currently no clear guidelines for the prognosis of Tfh cell lymphoma.
ANNALS OF HEMATOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Michael Winkelmann, Viktoria Blumenberg, Kai Rejeski, Veit L. Buecklein, Michael Ruzicka, Marcus Unterrainer, Christian Schmidt, Franziska J. Dekorsy, Peter Bartenstein, Jens Ricke, Michael Von Bergwelt-Baildon, Marion Subklewe, Wolfgang G. Kunz
Summary: This study examines the prognostic value of the International Metabolic Prognostic Index (IMPI) for patients with B-cell non-Hodgkin's lymphoma receiving CD19 chimeric antigen receptor T-cell therapy (CART). The study finds that IMPI has predictive value for progression-free survival (PFS) but not overall survival (OS) in the context of CART.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Immunology
Shidai Mu, Deyao Shi, Lisha Ai, Fengjuan Fan, Fei Peng, Chunyan Sun, Yu Hu
Summary: The study revealed that the IPI-IPM has independent prognostic significance for DLBCL patients, showing that high-risk patients had worse overall survival and were correlated with immune-related signaling pathways, high mutation rates, and upregulation of inhibitory immune checkpoints, suggesting a greater potential response to ICB therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Jung Hyun Her, Dominik Pretscher, Maria Patra-Kneuer, Juergen Schanzer, Sung Yoo Cho, Yu Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Christina Heitmueller, Martin Wilhelm, Stefan Steidl, Jan Endell
Summary: Tafasitamab is an Fc-modified monoclonal antibody that targets CD19 and induces antibody-dependent cellular cytotoxicity (ADCC) through the binding of Fc gamma RIIIa receptors. This study demonstrates that the combination of ex vivo-expanded allogeneic NK or autologous gamma delta T cells with Tafasitamab treatment enhances the antitumor effect of Tafasitamab, potentially offering a promising novel approach.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Adam J. Olszewski, Lasse H. Jakobsen, Graham P. Collins, Kate Cwynarski, Veronika Bachanova, Kristie A. Blum, Kirsten M. Boughan, Mark Bower, Alessia Dalla Pria, Alexey Danilov, Kevin A. David, Catherine Diefenbach, Fredrik Ellin, Narendranath Epperla, Umar Farooq, Tatyana A. Feldman, Alina S. Gerrie, Deepa Jagadeesh, Manali Kamdar, Reem Karmali, Shireen Kassam, Vaishalee P. Kenkre, Nadia Khan, Seo-Hyun Kim, Andreas K. Klein, Izidore S. Lossos, Matthew A. Lunning, Peter Martin, Nicolas Martinez-Calle, Silvia Montoto, Seema Naik, Neil Palmisiano, David Peace, Elizabeth H. Phillips, Tycel J. Phillips, Craig A. Portell, Nishitha Reddy, Anna Santarsieri, Maryam Sarraf Yazdy, Knut B. Smeland, Scott E. Smith, Stephen D. Smith, Suchitra Sundaram, Adam S. Zayac, Xiao-Yin Zhang, Catherine Zhu, Chan Y. Cheah, Tarec C. El-Galaly, Andrew M. Evens
Summary: The BL-IPI provides robust discrimination of survival in adult BL, suitable for use as prognostication and stratification in trials. The high-risk group has suboptimal outcomes with standard therapy and should be considered for innovative treatment approaches.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Jiwei Song, FeiMing Huang, Lei Chen, KaiYan Feng, Fangfang Jian, Tao Huang, Yu-Dong Cai
Summary: In this study, machine learning methods were used to analyze methylation signatures to differentiate CAR-transduced and untransduced T cells from patients with acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Important methylated genes were identified, providing a theoretical foundation for modifying CAR T cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Hikmat Abdel-Razeq, Mohammad Ma'koseh, Rashid Abdel-Razeq, Rula Amarin, Alaa Abufara, Razan Mansour, Mohammad Manasrah, Mohammad Al-Rwashdeh, Rayan Bater
Summary: VTE is commonly seen in lymphoma patients. Using IPI index, this study identified DLBCL patients at higher risk for VTE, particularly in those with poor performance status.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
N. George Mikhaeel, Martijn W. Heymans, Jakoba J. Eertink, Henrica C. W. de Vet, Ronald Boellaard, Ulrich Duhrsen, Luca Ceriani, Christine Schmitz, Sanne E. Wiegers, Andreas Huttmann, Pieternella J. Lugtenburg, Emanuele Zucca, Gerben J. C. Zwezerijnen, Otto S. Hoekstra, Josee M. Zijlstra, Sally F. Barrington
Summary: This study aimed to determine the best statistical relationship between metabolic tumor volume (MTV) and survival in diffuse large B-cell lymphoma (DLBCL), and compare it with the International Prognostic Index (IPI). The results showed that MTV was a better predictor for progression-free survival (PFS) and overall survival (OS) than IPI. A new prognostic model combining MTV, age, and stage outperformed IPI and provided individualized estimates of patient outcome.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Health Care Sciences & Services
Agata Puzzovivo, Agnese Maria Fioretti, Carla Minoia, Roberta Villoni, Santa Carbonara, Giusi Graziano, Fabio Pavone, Attilio Guarini, Stefano Oliva
Summary: This study evaluated the performance of the delta Tei index for early detection of cardiac toxicity in lymphoma patients treated with anthracyclines. The results suggest that the Tei index may predict the risk for cardiotoxicity earlier than changes in left ventricular ejection fraction.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Medicine, Research & Experimental
Shuhua Yi, Yuting Yan, Meiling Jin, Supriyo Bhattacharya, Yi Wang, Yiming Wu, Lu Yang, Eva Gine, Guillem Clot, Lu Chen, Ying Yu, Dehui Zou, Jun Wang, An T. Phan, Rui Cui, Fei Li, Qi Sun, Qiongli Zhai, Tingyu Wang, Zhen Yu, Lanting Liu, Wei Liu, Rui Lyv, Weiwei Sui, Wenyang Huang, Wenjie Xiong, Huijun Wang, Chengwen Li, Zhijian Xiao, Mu Hao, Jianxiang Wang, Tao Cheng, Silvia Bea, Alex F. Herrera, Alexey Danilov, Elias Campo, Vu N. Ngo, Lugui Qiu, Lili Wang
Summary: This study identified four distinct genetic subsets of mantle cell lymphoma (MCL) and demonstrated the impact of clonal evolution on clinical outcomes. These findings provide valuable insights into the heterogeneity of MCL and its genetic determinants.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Oncology
Titas Banerjee, Anusha Vallurupalli
Summary: Non-Hodgkin's lymphomas (NHL) are a group of lymphoproliferative disorders originating in different lymphocytes. First line therapy commonly involves a combination of steroids and chemotherapy, but treatment for relapsed/refractory (R/R) NHL remains challenging. New therapies focus on manipulating the body's immune mechanisms to target and eliminate tumor cells. This article reviews emerging immune and cell therapies for R/R B-NHL.
CURRENT PROBLEMS IN CANCER
(2022)
Article
Oncology
YuanBo Xue, Xun Lai, RuiLei Li, ChunLei Ge, BaoZhen Zeng, Zhen Li, QiaoFen Fu, LiuFang Zhao, SuWei Dong, JinYan Yang, JiYin Guo, QingYin Meng, QingHua Tan, ZhenHui Li, HaiYan Ding, YanLei Zhang, ShaoHui Liu, Alex H. Chang, Hong Yao, RongCheng Luo
Summary: The study indicated that combination therapy with anti-CD19 and CD30 CAR T-cells may be safe and effective for relapsed/refractory classical Hodgkin's Lymphoma patients. Only a small percentage of patients were found eligible for this treatment, but those who received it showed promising outcomes without severe adverse events. Further clinical trials are needed to explore the potential of CD19 and CD30 CAR T-cell combination therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Transplantation
Farzad Vafaei, Seyed Mohsen Dehghani, Seyed Ali Malekhoseini, Hamdollah Karamifar, Saman Nikeghbalian
EXPERIMENTAL AND CLINICAL TRANSPLANTATION
(2018)
Article
Gastroenterology & Hepatology
Bita Geramizadeh, Ali Kashkooe, Ali Bahador, Seyed Mohsen Dehghani, Alireza Shamsaeefar, Kurosh Kazemi, Seyed Ali Malekhosseini
Article
Gastroenterology & Hepatology
Mohammad Zarenezhad, Seyyed Mohsen Dehghani, Fardad Ejtehadi, Mohammad Reza Fattahi, Hasan Dastsouz, Majid Fardaei, Mohammad Bagher Tabei
Article
Cardiac & Cardiovascular Systems
Seyed Mohsen Dehghani, Mitra Moshref, Hamid Amoozgar, Seyed Ali Malek Hoseini, Saman Nikeghbalian
PEDIATRIC CARDIOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Mehdi Dehghani, Zahra Samani, Hassan Abidi, Leila Manzouri, Reza Mahmoudi, Saeed Hosseini Teshnizi, Mohsen Nikseresht
INTERNATIONAL JOURNAL OF GENOMICS
(2018)
Article
Biochemistry & Molecular Biology
Mohsen Nikseresht, Maryam Shahverdi, Mehdi Dehghani, Hassan Abidi, Reza Mahmoudi, Ghasem Ghalamfarsa, Leila Manzouri, Saeid Ghavami
JOURNAL OF CELLULAR BIOCHEMISTRY
(2019)
Article
Oncology
Mehdi Dehghani, Mehdi Kalani, Hossein Golmoghaddam, Mani Ramzi, Nargess Arandi
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2020)
Article
Oncology
Mehdi Dehghani, Negin Shokrgozar, Mani Ramzi, Mehdi Kalani, Hossein Golmoghaddam, Nargess Arandi
Summary: Selenium has long been recognized as a potential anti-cancer agent that can enhance immune cell function in solid tumors. A study involving non-Hodgkin lymphoma patients found that 3-month selenium supplementation did not significantly impact the frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells or the expression of immune checkpoint receptors. However, changes in a specific subset of Tregs were correlated with alterations in checkpoint receptor expression, and selenium supplementation did not prevent relapse in these patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Immunology
Mehdi Dehghani, Mani Ramzi, Mehdi Kalani, Hossein Golmoghaddam, Nargess Arandi
Summary: This study evaluated the polarization of Th1 and Th2 lymphocytes in lymphoma patients and found that increased peripheral blood Th2 cells may be associated with a favorable prognosis.
IMMUNOLOGICAL INVESTIGATIONS
(2022)
Article
Endocrinology & Metabolism
Mehdi Dehghani, Ali Mohammad Hobbi, Shirin Haghighat, Fariba Karimi, Mani Ramzi, Reza Vojdani, Mojtaba Karimi
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2020)
Article
Biochemistry & Molecular Biology
Mehdi Dehghani, Kevin P. Rosenblatt, Lei Li, Mrudula Rakhade, Robert J. Amato
FRONTIERS IN MOLECULAR BIOSCIENCES
(2019)
Article
Oncology
Mohammad Javad Khezeli, Mehdi Dehghani, Khosro Keshavarz, Zahra Kavosi
MIDDLE EAST JOURNAL OF CANCER
(2019)
Article
Medicine, Legal
Pedram Keshavarz, Mehdi Dehghani, Fatemeh Malekpour, Saeid Gholamzadeh, Mohammad Zarenezhad, Abdorrasoul Malekpour
EGYPTIAN JOURNAL OF FORENSIC SCIENCES
(2019)
Article
Transplantation
M. Zakerinia, A. Kamgarpour, H. Nemati, H. R. Zare, M. Ghasemfar, A. R. Rezvani, M. Karimi, H. Nourani Khojasteh, M. Dehghani, R. Vojdani, S. Haghighat, N. Namdari, J. Rekabpoor, M. Tavazo, S. Amirghofran, Z. Amirghofran, G. A. Yosefipour, M. Ramzi
INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE
(2018)
Article
Medicine, General & Internal
Mehdi Dehghani, Saranaz Jangjoo, Ahmad Monabati, Dena Masoomi Bandari, Nasrin Namdari
IRANIAN JOURNAL OF MEDICAL SCIENCES
(2018)